Conclusion
Appropriate and timely use of Sacubitril/Valsartan has the potential to significantly and swiftly improve LV function even in patients with acute decompensated HF, not only in chronic HF patients.
Based on these improved outcomes, it is necessary to make a change in clinical practice to early implement this lifesaving therapy in acute decompensated HF patients.
Usually when medications improve quality of life, the patient’s adherence increases. Our patient was highly adherent to his medications after he experienced the significant improvement of his symptoms.
The outstanding impact of multimodality imaging and precisely 2D Echocardiography is obvious in monitoring improvement of cardiac function and deciding for revascularization
Echocardiography is the most useful test providing immediate information, including improvement of systolic and diastolic function of LV and RV, chamber size, and reduction in severity of valvular regurgitation and pulmonary pressure with OMT including ARNI as in our patient.
A cknowledgement
None.